Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

In the two last decades, proteases have constituted one of the primary and important targets in drug discovery. The U.S. FDA has approved more than 12 protease therapies in the last 10 years, and a number of next-generation or completely new proteases are under clinical development. Protease inhibition strategies are one of the fastest expanding areas in the field of of drugs that show considerable promise. This Special Issue will focus on the recent advances in the discovery and development of protease inhibitors, covering the synthesis of protease inhibitors, the design of new chemical entities acting as inhibitors of special/particular types of proteases, and their mode of actions (Frolova et al. 2020; Slapak et al. 2020; Künnapuu et al. 2021). In addition, the new applications of these interesting compounds/biomolecules and their limitations have been discussed and described (Wang et al. 2020; Bartošová-Sojková et al. 2021).

Research & information: general --- MMP --- MMP2 --- MMP9 --- MMP7 --- MMP14 --- matrix metalloproteases --- PDAC --- pancreatic cancer --- Bowman–Birk inhibitor --- ranacyclin --- trypsin inhibitor --- structure–activity relationship --- synergistic effect --- Gentamicin --- matrix metalloproteinase --- extracellular matrix --- nuclei --- cancer --- apoptosis --- immune response --- cysteine protease inhibitor --- stefin --- signal peptide --- parasite --- phylogenetic analysis --- diversification --- protein structure --- vascular endothelial growth factors (VEGFs) --- VEGF-A --- PlGF --- VEGF-B --- VEGF-C --- VEGF-D --- angiogenesis --- lymphangiogenesis --- CCBE1 --- proteases --- ADAMTS3 --- plasmin --- cathepsin D --- KLK3 --- prostate-specific antigen (PSA) --- thrombin --- wound healing --- metastasis --- proteolytic activation --- vascular biology --- lymphedema

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

In the two last decades, proteases have constituted one of the primary and important targets in drug discovery. The U.S. FDA has approved more than 12 protease therapies in the last 10 years, and a number of next-generation or completely new proteases are under clinical development. Protease inhibition strategies are one of the fastest expanding areas in the field of of drugs that show considerable promise. This Special Issue will focus on the recent advances in the discovery and development of protease inhibitors, covering the synthesis of protease inhibitors, the design of new chemical entities acting as inhibitors of special/particular types of proteases, and their mode of actions (Frolova et al. 2020; Slapak et al. 2020; Künnapuu et al. 2021). In addition, the new applications of these interesting compounds/biomolecules and their limitations have been discussed and described (Wang et al. 2020; Bartošová-Sojková et al. 2021).

Research & information: general --- MMP --- MMP2 --- MMP9 --- MMP7 --- MMP14 --- matrix metalloproteases --- PDAC --- pancreatic cancer --- Bowman–Birk inhibitor --- ranacyclin --- trypsin inhibitor --- structure–activity relationship --- synergistic effect --- Gentamicin --- matrix metalloproteinase --- extracellular matrix --- nuclei --- cancer --- apoptosis --- immune response --- cysteine protease inhibitor --- stefin --- signal peptide --- parasite --- phylogenetic analysis --- diversification --- protein structure --- vascular endothelial growth factors (VEGFs) --- VEGF-A --- PlGF --- VEGF-B --- VEGF-C --- VEGF-D --- angiogenesis --- lymphangiogenesis --- CCBE1 --- proteases --- ADAMTS3 --- plasmin --- cathepsin D --- KLK3 --- prostate-specific antigen (PSA) --- thrombin --- wound healing --- metastasis --- proteolytic activation --- vascular biology --- lymphedema

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The only effective and safe treatment of celiac disease (CD) is a lifelong, strict exclusion of gluten, the so-called gluten-free diet (GFD). As a consequence, strict adherence to the GFD is highly successful and useful to achieve optimal control of symptoms in celiac patients, although, sometimes, nutritional problems can persist despite a strict exclusion of gluten. However, following a strict GFD is not easy and an updated quality assessment of available products is needed for further improvement in gluten-free product development. Similar to CD, GFD is the common dietary approach in non-celiac gluten/wheat sensitivity (NCGWS). NCGWS is another common gluten-related disorder without the diagnostic features of CD. Increasing interest in the association and interaction between irritable bowel syndrome (IBS), functional dyspepsia, and gluten-related disorders can expand our knowledge and understanding of the management of these disorders. In this respect, GFD is considered a therapeutic option in IBS and functional digestive disorders. New insights into the GFD are an exciting scientific challenge for researchers.

irritable bowel syndrome --- celiac disease --- nonceliac gluten/wheat sensitivity --- gluten-free diet --- AIDAI score --- amylase trypsin inhibitor --- non-celiac wheat sensitivity --- CD14 lymphocytes --- interleukin-1beta --- tumor necrosis factor-α --- non coeliac wheat sensitivity --- gluten --- FODMAPs --- functional dyspepsia --- Celiac disease --- iron deficiency without anemia --- dietary iron --- iron supplementation --- women --- refractory celiac disease --- remission --- nickel allergy --- allergic contact mucositis --- irritable bowel syndrome (IBS) --- low-nickel diet --- gluten-free products --- gluten containing products --- food composition database --- dietary reference intake --- prison diets --- irritable bowel disease --- FODMAP --- low FODMAP diet --- gluten free diet --- non-celiac gluten wheat sensitivity --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Protease Inhibitors. --- Trypsin Inhibitors. --- Enzyme inhibitors --- -Proteinase --- -Proteolytic enzymes --- Antagonists, Enzyme --- Enzyme antagonists --- Enzymes --- Inhibitors, Enzyme --- Metabolic inhibitors --- Chemical inhibitors --- Inhibitors, Trypsin --- Trypsin --- Antiproteases --- Protease Inhibitor --- Endopeptidase Inhibitors --- Peptidase Inhibitors --- Peptide Hydrolase Inhibitors --- Peptide Peptidohydrolase Inhibitors --- Protease Antagonists --- Antagonists, Protease --- Hydrolase Inhibitors, Peptide --- Inhibitor, Protease --- Inhibitors, Endopeptidase --- Inhibitors, Peptidase --- Inhibitors, Peptide Hydrolase --- Inhibitors, Peptide Peptidohydrolase --- Inhibitors, Protease --- Peptidohydrolase Inhibitors, Peptide --- Peptide Hydrolases --- Endopeptidases --- Exopeptidases --- Proteinase Inhibitory Proteins, Secretory --- Congresses --- Antagonists --- Inhibitors --- antagonists & inhibitors --- Proteinase --- Congresses. --- -Congresses --- Protease Inhibitors --- Trypsin Inhibitors --- Proteolytic enzymes --- Trypsin Inhibitor --- Inhibitor, Trypsin --- Antiprotease --- Endopeptidase Inhibitor --- Peptidase Inhibitor --- Peptide Hydrolase Inhibitor --- Peptide Peptidohydrolase Inhibitor --- Protease Antagonist --- Antagonist, Protease --- Hydrolase Inhibitor, Peptide --- Inhibitor, Endopeptidase --- Inhibitor, Peptidase --- Inhibitor, Peptide Hydrolase --- Inhibitor, Peptide Peptidohydrolase --- Peptidohydrolase Inhibitor, Peptide